Evidence map›Paper›PMID 36358611›Full record

ArticleCancers2022

Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later.

Monica Ribeiro, Mohamed Amine Benadjaoud, Laura Moisy, Julian Jacob, Loïc Feuvret, Alexander Balcerac, Marie-Odile Bernier, Dimitri Psimaras, Khê Hoang-Xuan, Georges Noel and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Symptom network and latent profile analysis in patients after glioma surgery: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Monica RibeiroPitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France.ORCID 0000-0003-0834-1750
Mohamed Amine BenadjaoudInstitute for Radiological Protection and Nuclear Safety, Direction of Human Health, Radiobiology and Regenerative Medicine Research Service, 92260 Fontenay-aux-Roses, France.ORCID 0000-0002-9895-6654
Laura MoisyICANS-Strasbourg-Europe Cancer Institute, Clinical Research Department, 67200 Strasbourg, France.
Julian JacobPitié-Salpêtrière-Charles Foix Hospital Group, Radiation Oncology Department, Sorbonne University, 75013 Paris, France.
Loïc FeuvretPitié-Salpêtrière-Charles Foix Hospital Group, Radiation Oncology Department, Sorbonne University, 75013 Paris, France.
Alexander BalceracCNRS, ENS Paris-Saclay, Centre Borelli, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.ORCID 0000-0003-1686-0681
Marie-Odile BernierInstitute for Radiological Protection and Nuclear Safety, Direction of Human Health, Radiobiology and Regenerative Medicine Research Service, 92260 Fontenay-aux-Roses, France.ORCID 0000-0001-5807-4596
Dimitri PsimarasPitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France.
Khê Hoang-XuanPitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France.
Georges NoelICANS-Strasbourg-Europe Cancer Institute, Radiation Oncology Department, 67200 Strasbourg, France.ORCID 0000-0003-4952-5572
Nathalie Jouniaux-DelbezPitié-Salpêtrière-Charles Foix Hospital Group, Neuro-Oncology Departement, Sorbonne University, 75013 Paris, France.
Damien RicardCNRS, ENS Paris-Saclay, Centre Borelli, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.
Sorbonne Université · FRCentre National de la Recherche Scientifique · FRInstitut de Cancérologie Strasbourg · FR

Funding

Institut du Cerveau S.WP13.03.RICARD .
6 · The paper itself

Abstract

High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients' well-being and quality of life.

Indexed as

anxietydepressionhigh-grade gliomapalliative carequality of life

Identifiers

PMID36358611
PMCPMC9659261
OpenAlexW4307327754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.